drugset
drugset / Trial / NCT00420706

Study Evaluating SCA-136 Tolerability With Dose Titration and Food

NCT00420706 ↗

Phase 1 Terminated 120 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate whether the tolerability of SCA-136 is improved by dosing with food or by increasing dose amounts in a step-wise fashion.

Timeline

Start
2006-12
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject vabicaserin Small molecule — —

Indications

No indication recorded.